Mia Cassella told Newsweek: "Cancer might take away things like my hair or my energy, but it couldn't take away my passion for lifting and working out." ...

Health experts say popular weight-loss drugs like Ozempic and Wegovy are safe, but the FDA warns counterfeits are becoming more widespread.

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Ozempic and similar drugs are popular with consumers for their weight-loss properties, but a new study suggests they could ...

Novo Nordisk is planning a new Phase III trial for CagriSema ... the weight loss seen after 68 weeks might not have been the ...

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health ...

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks ... your rights to seek a recovery. There is no cost or obligation to participate.

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks ... your rights to seek a recovery. There is no cost or obligation to participate.

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks ... that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may ...

The experimental CagriSema shot missed Novo’s own expectations for weight loss and performed roughly in-line with Eli Lilly & Co.’s Zepbound, which is already on the market and competes with the ...

While the initial market reaction to Novo’s more enhanced CagriSema weight loss treatment was negative, we believe this is a more potent formulation that can better compete with Lilly’s suite.

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks ... 2025. There is no cost or obligation to you to participate in this case.